All In Biotech

Drug Trial Radar · NCT07728721

Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis

A Randomised, Double-blind, Placebo-controlled Parallel Group Phase II Clinical Study Evaluating the Efficacy and Safety of HSK50042 in Subjects With Idiopathic Pulmonary Fibrosis

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

175

Planned (sponsor's estimate)

Start

Aug 25, 2026

Primary completion

Apr 10, 2028

Study completion Jul 25, 2028

Sponsor

Sponsor type
Industry
First posted
Jul 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

  • HSK50042 dose 1Drug

    HSK50042 taken orally once daily in the morning for 26 weeks.

  • HSK50042 dose 2Drug

    HSK50042 taken orally once daily in the morning for 26 weeks.

  • HSK50042 dose 3Drug

    HSK50042 taken orally once daily in the morning for 26 weeks.

  • PlaceboDrug

    Placebo matching HSK50042 taken orally once daily in the morning for 26 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change from baseline in forced vital capacity (FVC) at week 12Time frame: week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.